title: Guillain-Barré Syndrome following Treatment with Sunitinib Malate.
abstract: Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)-resistant gastrointestinal stromal tumor (GIST) with few reported side effects including asthenia, myelosuppression, diarrhea, and mucositis. Scarce literature exists regarding the rare but often serious toxicities of sunitinib. Autoimmune and neurological side effects have been linked to sunitinib's inhibition of VEGF receptors with a corresponding increase in VEGF levels, which is associated with development of different neuropathies. We hereby report an interesting case of Guillain-Barré syndrome in a middle-aged patient with metastatic renal cell carcinoma following sunitinib treatment.
authors.affiliation: Department of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USA.
authors.forename: Ziad
authors.identifier: 0000-0001-5376-562X
authors.initials: Z
authors.lastname: Kanaan
authors.affiliation: Department of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USA.
authors.forename: Zain
authors.identifier: 0000-0002-5015-1320
authors.initials: Z
authors.lastname: Kulairi
authors.affiliation: Department of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USA.
authors.forename: Mirela
authors.identifier: 0000-0002-1116-5834
authors.initials: M
authors.lastname: Titianu
authors.affiliation: Department of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USA.
authors.forename: Sandip
authors.initials: S
authors.lastname: Saha
authors.affiliation: Department of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USA.
authors.forename: Sarwan
authors.initials: S
authors.lastname: Kumar